基于组织芯片的大样本原发中枢神经系统淋巴瘤分子特征分析
该研究利用组织芯片对115例免疫功能正常的原发中枢神经系统淋巴瘤(PCNSL)患者进行免疫组化和荧光原位杂交检测,评估多种分子特征的分布及预后影响。多数病例为非生发中心B细胞表型,MYC、BCL2和PD-L1蛋白表达常见但基因重排罕见,BCL6重排是唯一与不良预后相关的因素。
要点
- BCL6重排(31%)是唯一与较差预后相关的分子因素。
- MYC、BCL2和PD-L1蛋白表达常见但相应基因重排罕见。
- 多数病例为非生发中心B细胞表型,但细胞起源不影响生存。
核心结论
- PCNSL的分子特征独特,不同于系统性DLBCL,BCL6重排是唯一与不良预后相关的因素。
研究设计与样本
- 基于BC Cancer淋巴肿瘤临床和病理数据库识别115例免疫功能正常的PCNSL(DLBCL组织学)患者,利用档案FFPE诊断活检组织构建组织芯片,进行免疫组化和FISH检测。
主要发现
- ≥75%的病例为非生发中心B细胞表型,但细胞起源不影响无进展生存或总生存。
- MYC(40%)、BCL2(75%)和PD-L1(29%)蛋白表达常见,但相应基因重排罕见(每种≤1%)。
- 无MYC和BCL2双重重排。
- 仅22%的病例有MHC II类分子膜表达。
- 1例免疫功能正常患者EBER阳性。
关键数值与推荐
- BCL6重排频率为31%,是唯一与较差预后相关的因素。
- MYC、BCL2、PD-L1蛋白表达率分别为40%、75%、29%,相应基因重排各≤1%。
- 非生发中心B细胞表型占≥75%。
- MHC II类分子膜表达仅占22%。
临床怎么用
- PCNSL的分子特征与系统性DLBCL不同,可能指导药物开发。
- BCL6重排可识别预后不良的PCNSL患者。
局限性
- 样本量有限(115例),BCL6重排亚组分析基于52例接受大剂量甲氨蝶呤治疗的患者。
- 仅基于组织芯片和免疫组化/FISH,未进行全面的分子测序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to evaluate the distribution and prognostic impact of a broad range of molecular attributes in a large cohort of immunocompetent patients with primary central nervous system lymphoma (PCNSL) by using tissue microarray. Patients diagnosed with PCNSL were initially identified in the BC Cancer Lymphoid Cancer clinical and pathology databases. Tissue microarrays were constructed by using archival formalin-fixed paraffin-embedded diagnostic biopsy tissue. Immunohistochemistry and fluorescent in situ hybridization studies were performed. A total of 115 patients with PCNSL with diffuse large B-cell lymphoma (DLBCL) histology were identified. The majority of cases (≥75%) had a non-germinal center B-cell phenotype according to immunohistochemistry algorithms, but cell of origin did not affect progression-free or overall survival. MYC (40%), BCL2 (75%), and programmed death-ligand 1 (29%) protein expression were common, but their corresponding gene rearrangements were rare (≤1% each), suggesting that alternate mechanisms were driving expression. There were no dual rearrangements involving MYC and BCL2. Only 22% of cases had membranous expression of major histocompatibility complex class II, suggesting a mechanism for escape from immune surveillance. Epstein-Barr virus-encoded RNA was positive in 1 immunocompetent patient. BCL6 protein expression (77%) and BCL6 rearrangements (31%) were frequent; the latter was the only factor associated with a poor prognosis in the overall cohort and in the subgroup of 52 patients treated with high-dose methotrexate-based regimens. This large population-based study shows that prominent molecular features of PCNSL are unique and different from those of systemic DLBCL. These results may better inform drug development in PCNSL.
引用
- Villa D, Tan KL, Steidl C, et al. Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. Blood Adv. 2019. PMID: 31805190. doi:10.1182/bloodadvances.2019000989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。